Cognetivity Neurosciences Announces Collaboration With Alzheimer's Society to Further Expand Its AI Algorithms
Cognetivity Neurosciences Announces Collaboration With Alzheimer's Society to Further Expand Its AI Algorithms
Agreement aims at further development of Cognetivity's AI (Artificial Intelligence) platform through investigating comorbidities in diabetes and dementia
协议旨在通过研究糖尿病和痴呆症的共病来进一步开发Cognetivity的AI(人工智能)平台
Vancouver, British Columbia--(Newsfile Corp. - May 31, 2023) - Cognetivity Neurosciences Ltd. (CSE: CGN) (OTCQB: CGNSF) (FSE: 1UB) ("the Company" or "Cognetivity"), a leading provider of brain health solutions powered by AI, is excited to announce a collaboration with the Alzheimer's Society in Oman. This partnership aims to study cognitive health in patients with dementia and diabetes.
不列颠哥伦比亚省温哥华--(Newsfile Corp.-2023年5月31日)-领先的人工智能脑健康解决方案提供商Cognetivity NeuroSciences Ltd.(CSE:CGN)(OTCQB:CGNSF)(FSE:1UB)(以下简称“本公司”或“Cognetivity”)兴奋地宣布与阿曼阿尔茨海默氏症协会达成合作。这项合作旨在研究痴呆症和糖尿病患者的认知健康。
Cognetivity Neurosciences is renowned for its innovative Integrated Cognitive Assessment (CognICA) platform, a state-of-the-art tool that combines artificial intelligence and neuroscience to provide rapid, accurate, and accessible cognitive assessments. Alzheimer's Society Oman is a member of Alzheimer's Disease International (ADI), a not-for-profit, international federation of Alzheimer and dementia associations from around the world working closely with the World Health Organization (WHO). ADI advocates for people living with Alzheimer's disease and all other types of dementia.
认知神经科学以其创新的综合认知评估(CognICA)平台而闻名,这是一种最先进的工具,将人工智能和神经科学相结合,提供快速、准确和可访问的认知评估。阿曼阿尔茨海默氏症协会是阿尔茨海默病国际(ADI)的成员,ADI是一个由来自世界各地的阿尔茨海默氏症和痴呆症协会组成的非营利性国际联合会,与世界卫生组织(WHO)密切合作。ADI倡导患有阿尔茨海默病和所有其他类型痴呆症的人。
The collaboration will be focused on regular monitoring of the senior population presenting to the healthcare services provided by the Omani Ministry of Health. The primary objective is to create a baseline performance of the senior population brain health using CognICA. In addition, the collaboration's aim is to investigate comorbidities such as diabetes in patients diagnosed with dementia or Alzheimer's disease using big data, allowing for further development of AI models that enable risk stratification.
合作的重点将是定期监测接受阿曼卫生部提供的保健服务的老年人口。主要目标是使用CognICA创建老年人群脑健康的基线表现。此外,合作的目的是使用大数据调查被诊断为痴呆症或阿尔茨海默病的患者的糖尿病等共病,从而进一步开发能够进行风险分层的人工智能模型。
People living with dementia often have a higher prevalence of diabetes as a comorbidity. This relationship can be attributed to shared risk factors such as age, obesity, sedentary lifestyle, and vascular complications. Moreover, the presence of diabetes has been shown to accelerate cognitive decline in individuals with dementia, potentially worsening their overall prognosis and management. Understanding the interplay between these two conditions is crucial for healthcare professionals to provide comprehensive care and develop tailored strategies that address both the cognitive and metabolic aspects of the individual's health. By recognizing and managing comorbidities effectively, healthcare providers can optimize the well-being and quality of life for those affected by dementia and diabetes.
患有痴呆症的人通常有更高的糖尿病共病患病率。这种关系可以归因于共同的风险因素,如年龄、肥胖、久坐的生活方式和血管并发症。此外,糖尿病的存在已被证明会加速痴呆症患者的认知能力下降,可能会恶化他们的整体预后和管理。了解这两种疾病之间的相互作用对于医疗专业人员提供全面的护理和制定针对个人健康的认知和代谢方面的策略至关重要。通过有效地识别和管理合并症,医疗保健提供者可以优化受痴呆症和糖尿病影响的人的福祉和生活质量。
Cognetivity's CIO, Dr Seyed Razavi commented "We are very pleased to be collaborating with the Alzheimer's Society on this very important area, which builds on our exponentially growing database and expanding AI model in a new population which brings further validation to our CognICA platform's transformative capabilities in both clinical practice and research."
Cognetivity首席信息官Seed Razavi博士表示:“我们非常高兴能在这一非常重要的领域与阿尔茨海默氏症协会合作,这一领域建立在我们呈指数级增长的数据库和在新人群中扩展的人工智能模型的基础上,这进一步验证了我们CognICA平台在临床实践和研究方面的变革能力。”
Dr. Hamed Al Sinawi, Chairman of Alzheimer's Society Oman, added "Cognetivity's technology's unique combination of high precision, speed of administration and repeatability allows us to measure with greater precision in this important and groundbreaking area of research. We are excited to be able to measure small changes in cognition in these often overlooked patients, giving us greater understanding of the interactions between these diseases and improving our ability to deliver help when it is most effective."
阿曼阿尔茨海默氏症协会主席哈米德·阿尔·西纳维博士补充道:“Cognetivity的技术结合了高精确度、管理速度和重复性,使我们能够在这一重要而开创性的研究领域进行更精确的测量。我们很高兴能够测量这些经常被忽视的患者的认知的微小变化,让我们更好地了解这些疾病之间的相互作用,并提高我们在最有效的时候提供帮助的能力。”
About Cognetivity Neurosciences
关于认知神经科学
Cognetivity is a technology company that has developed a cognitive testing platform for use in medical, commercial, and consumer environments. Cognetivity's CognICA uses artificial intelligence and machine learning technology to test the performance of large areas of the brain to help detect early signs of cognitive dysfunction. CognICA is currently available for clinical use in the United States, United Kingdom, Europe, and the Middle East, with regulatory approval in other regions expected in 2023.
Cognetivity是一家技术公司,它开发了一种认知测试平台,用于医疗、商业和消费环境。Cognetivity的CognICA使用人工智能和机器学习技术来测试大脑大片区域的表现,以帮助检测认知功能障碍的早期迹象。CognICA目前可在美国、英国、欧洲和中东用于临床,预计2023年将在其他地区获得监管批准。
On behalf of the Board of Directors
我谨代表董事会
"Sina Habibi"
Sina Habibi
Chief Executive Officer and Director
《新浪哈比比》
新浪哈比比
董事首席执行官兼首席执行官
Forward-looking statements:
前瞻性陈述:
Certain statements contained in this news release, including those identified by the words "anticipate," "assume," "believe," "plan," "estimate," "expect," "intend," "may," "should" and similar expressions, to the extent they relate to the Company or its management, constitute forward-looking information or statements (collectively, the "Forward-Looking Statements"). These forward-looking statements are not historical facts and reflect current expectations regarding future results or events. This news release contains forward-looking statements. These forward-looking statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Such statements are based on current expectations and various estimates, factors and assumptions, and involve known and unknown risks, uncertainties and other factors. Such statements and information are based on a number of assumptions regarding our current and future business strategies and the environment in which we operate. We assume no responsibility to update or revise forward-looking information to reflect new events or circumstances, except as required by law. Readers are cautioned not to place undue reliance on our forward-looking statements.
本新闻稿中包含的某些陈述,包括“预期”、“假设”、“相信”、“计划”、“估计”、“预期”、“打算”、“可能”、“应该”以及类似的表述,在与公司或其管理层有关的范围内,构成前瞻性信息或陈述(统称为“前瞻性陈述”)。这些前瞻性陈述不是历史事实,反映了对未来结果或事件的当前预期。本新闻稿包含前瞻性陈述。这些前瞻性陈述不是对未来业绩的保证,涉及难以预测的风险、不确定性和假设。此类陈述基于当前预期和各种估计、因素和假设,涉及已知和未知的风险、不确定性和其他因素。这些陈述和信息是基于对我们当前和未来的业务战略以及我们所处的经营环境的一些假设。除法律要求外,我们不承担更新或修改前瞻性信息以反映新事件或新情况的责任。告诫读者不要过度依赖我们的前瞻性陈述。
The Canadian Securities Exchange is not responsible for the adequacy or accuracy of this release.
加拿大证券交易所不对本新闻稿的充分性或准确性负责。
For more information, please visit: website: or contact: info@cognetivity.com; media inquiries can be sent to pr@cognetivity.com.
欲了解更多信息,请访问网站:或联系方式:info@cognetivity.com;媒体查询可发送至pr@cognetivity.com。
To view the source version of this press release, please visit
要查看本新闻稿的源版本,请访问